


## JNJ-39758979

Cat. No.:	HY-101189
CAS No.:	1046447-90-8
Molecular Formula:	C <sub>11</sub> H <sub>19</sub> N <sub>5</sub>
Molecular Weight:	221.3
Target:	Histamine Receptor
Pathway:	GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 33.33 mg/mL (150.61 mM; Need ultrasonic)						
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg	
				1 mM	4.5188 mL	22.5938 mL	45.1875 mL
				5 mM	0.9038 mL	4.5188 mL	9.0375 mL
				10 mM	0.4519 mL	2.2594 mL	4.5188 mL
Please refer to the solubility information to select the appropriate solvent.							
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 3.5 mg/mL (15.82 mM); Clear solution						
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 3.5 mg/mL (15.82 mM); Clear solution						
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 3.5 mg/mL (15.82 mM); Clear solution						

### BIOLOGICAL ACTIVITY

Description	JNJ-39758979 is a selective, orally active, and high-affinity histamine H <sub>4</sub> receptor antagonist with K <sub>i</sub> s of 12.5, 5.3, and 25 nM for human, mouse, and monkey histamine H <sub>4</sub> receptor, respectively. JNJ-39758979 functionally antagonizes histamine-induced cAMP inhibition with a pA <sub>2</sub> of 7.9 in transfected cells. JNJ-39758979 shows good anti-inflammatory and antipruritic activity <sup>[1][2]</sup> .			
IC <sub>50</sub> & Target	Human H <sub>4</sub> Receptor 12.5 nM (Ki)	Mouse H <sub>4</sub> Receptor 5.3 nM (Ki)	Monkey H <sub>4</sub> receptor 25 nM (Ki)	Rat H <sub>4</sub> receptor 188 nM (Ki)
	Guinea pig H <sub>4</sub> receptor			

	306 nM (K <sub>i</sub> )								
<b>In Vitro</b>	<p>JNJ 39758979 is a selective, high-affinity histamine H<sub>4</sub> receptor antagonist with a K<sub>i</sub> of 12.5 nM versus the human H<sub>4</sub> receptor and functionally antagonizes histamine-induced cAMP inhibition with a pA<sub>2</sub> of 7.9 in transfected cells. At the mouse H<sub>4</sub>R, the K<sub>i</sub>=5.3 nM and the pA<sub>2</sub>=8.3. At the monkey H<sub>4</sub>R, the K<sub>i</sub>=25 nM and the pA<sub>2</sub>=7.5. The affinity for the rat (K<sub>i</sub>=188 nM, pA<sub>2</sub> = 7.2) and guinea pig H<sub>4</sub>R (K<sub>i</sub>=306 nM) is moderate, and JNJ 39758979 has little if any affinity for the dog H<sub>4</sub>R (K<sub>i</sub>≥10 μM). The compound is highly selective for H<sub>4</sub>R, as it exhibits low affinity for the H<sub>1</sub>, H<sub>2</sub>, and H<sub>3</sub> receptors<sup>[1]</sup>.</p> <p>JNJ-39758979 is metabolically stable (t<sub>1/2</sub> &gt;120 min) when incubated in vitro with human, rat, dog, or monkey liver microsomes<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>								
<b>In Vivo</b>	<p>JNJ-39758979 (10 mg/kg; p.o.) treatment shows that the C<sub>max</sub>, t<sub>1/2</sub> and F values are 0.3 μM, 7.5 hours, and 36%, respectively <sup>[1]</sup>.</p> <p>JNJ-39758979 (2 mg/kg; i.v.) treatment shows that the V<sub>ss</sub>, AUC, CL and t<sub>1/2</sub> were 19.9 L/kg, 1.4 μM*h, 2.2 L/h, and 2.1 hours, respectively <sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Sprague-Dawley rats<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>10 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Oral administration (Pharmacokinetic Analysis)</td> </tr> <tr> <td>Result:</td> <td>The C<sub>max</sub>, t<sub>1/2</sub> and F values were 0.3 μM, 7.5 hours, and 36%, respectively.</td> </tr> </table>	Animal Model:	Sprague-Dawley rats <sup>[1]</sup>	Dosage:	10 mg/kg	Administration:	Oral administration (Pharmacokinetic Analysis)	Result:	The C <sub>max</sub> , t <sub>1/2</sub> and F values were 0.3 μM, 7.5 hours, and 36%, respectively.
Animal Model:	Sprague-Dawley rats <sup>[1]</sup>								
Dosage:	10 mg/kg								
Administration:	Oral administration (Pharmacokinetic Analysis)								
Result:	The C <sub>max</sub> , t <sub>1/2</sub> and F values were 0.3 μM, 7.5 hours, and 36%, respectively.								

## REFERENCES

[1]. Savall BM, et al. Discovery and SAR of 6-alkyl-2,4-diaminopyrimidines as histamine H<sub>4</sub> receptor antagonists. J Med Chem. 2014 Mar 27;57(6):2429-39.

[2]. Murata Y, et al. Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a H<sub>4</sub> R-antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitis.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA